Condition: Thoracoabdominal Aortic Aneurysm · Sponsor: W.L.Gore & Associates
Prospective, non-randomized, , multicenter study with two independent arms: * Primary Study Arm - TAAA and Pararenal aneurysms requiring only TAMBE System. Hypothesis-driven analysis. * Up to 65 additional subjects may be implanted in Continued Access Phase under the Primary Study Arm only * Secondary Study Arm - TAAA requiring TAMBE System and CTAG Device(s). Non hypothesis-driven analysis. Minimum: 122 implanted subjects. Maximum: 202 implanted subjects with up to 65 additional subjects implanted in Continued Access (Primary Study arm)
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| University of Alabama at Birmingham | Birmingham, Alabama, United States | — |
| Mayo Clinic Arizona | Scottsdale, Arizona, United States | — |
| Keck Medical Center of USC | Los Angeles, California, United States | — |
| Cedars-Sinai Medical Center | Los Angeles, California, United States | — |
| Kaiser Permanente San Francisco Medical Center | San Francisco, California, United States | — |
| Stanford University | Stanford, California, United States | — |
| MedStar Health Research Institute - MedStar Washington Hospital | Washington D.C., District of Columbia, United States | — |
| University of Florida - Gainesville | Gainesville, Florida, United States | — |
| University of South Florida | Tampa, Florida, United States | — |
| Emory University Hospital | Atlanta, Georgia, United States | — |
| Northwestern University | Chicago, Illinois, United States | — |
| Indiana University | Indianapolis, Indiana, United States | — |
+ 32 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.